Research Use Only. The information presented here is for scientific and educational purposes. These compounds are not intended for human consumption, self-administration, or therapeutic use.
Introduction
Peptide bioregulators are a research class of very short peptides, typically di-, tri-, and tetrapeptides, that are studied for their proposed ability to influence gene expression. The concept is closely associated with the work of Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, which is why these molecules are frequently described in the literature as Khavinson peptides. Unlike larger signaling peptides that act primarily at cell-surface receptors, short peptide bioregulators are investigated as candidate regulators that may reach the cell nucleus and interact with DNA and its associated chromatin proteins.
This overview surveys peptide bioregulators as a preclinical research topic. The material below summarizes how the class is defined, the gene-regulation and epigenetic hypotheses that motivate laboratory study, and the model systems in which these compounds have been examined. Every statement is framed in terms of what has been investigated in cell cultures and animal models. These compounds are supplied for research use only, not for human consumption, and no human longevity or therapeutic outcome is claimed or implied.
What Are Peptide Bioregulators?
The term peptide bioregulator refers to a family of short peptides originally investigated as tissue-derived regulatory factors. Early research focused on cytomedins, which are polypeptide complexes extracted from animal tissues such as the thymus, the pineal gland, and the vascular wall. Investigators later identified short peptide fragments believed to carry much of the regulatory activity, and these were reproduced as fully synthetic sequences sometimes called cytogens. The synthetic route allowed researchers to study defined molecules of known sequence rather than complex, variable tissue extracts.
From Tissue Extracts to Synthetic Short Peptides
A central idea in this research program is tissue specificity: each short peptide is hypothesized to show affinity for the tissue from which its parent complex was isolated. For example, thymus-associated peptides such as Vilon (Lys-Glu) have been examined in immune-cell models, while pineal-associated sequences such as Epitalon (Ala-Glu-Asp-Gly) have been studied in the context of circadian and cellular-aging assays. Whether this tissue-specific behavior reflects a distinct molecular mechanism or a more general property of small, charged peptides remains an open research question.
A Distinct Class from Peptide Hormones
Peptide bioregulators are conceptually separate from peptide hormones and growth factors. Classical peptide hormones are usually longer chains that bind defined membrane receptors and trigger established signaling cascades. Short peptide bioregulators, by contrast, are studied under the hypothesis that they act at the level of the genome itself. This places them in a different investigational category, and it is one reason the class continues to attract attention in molecular gerontology and epigenetics research.
The Gene-Regulation and Epigenetic Hypothesis
The defining research question around peptide bioregulators is whether very short peptides can modulate gene expression. Several laboratory models have been used to probe this idea, and the proposed mechanisms center on direct and indirect interactions with nucleic acids.
The Proposed DNA-Binding Model
One hypothesis holds that short peptides can enter the cell and the nucleus and then engage specific sequences within gene promoter regions. Under this complementary interaction model, the chemical properties of a peptide (its charge, size, and side-chain arrangement) allow it to associate with particular DNA motifs and thereby influence whether nearby genes are transcribed. Molecular-modeling and binding studies have been used to explore how di- and tetrapeptides might dock into the grooves of double-stranded DNA. These remain mechanistic hypotheses under active investigation rather than settled facts.
Epigenetic Observations in Cell Models
A second line of study frames peptide bioregulators as possible epigenetic modulators. Reported observations in cell systems include changes in DNA methylation patterns and altered chromatin compaction, such as the decondensation of heterochromatin in cultured lymphocytes exposed to certain short peptides. Because epigenetic marks govern how tightly DNA is packaged and how readily it is read, any compound that reproducibly shifts these marks is of interest for basic research into gene regulation. It is important to note that such findings are drawn from in-vitro and animal work and have not established any clinical effect.
Representative Short Peptides in the Research Literature
Several named short peptides recur across the peptide-bioregulator literature. They differ in sequence length and amino acid composition, which is central to how researchers compare them. The values in the table below reflect commonly reported laboratory attributes and are provided for comparison only.
| Research name | Amino acid sequence | Class | Approx. molecular weight | Tissue association studied |
|---|---|---|---|---|
| Epitalon (Epithalon) | Ala-Glu-Asp-Gly | Tetrapeptide | ~390 Da | Pineal-associated |
| Vilon | Lys-Glu | Dipeptide | ~275 Da | Thymus-associated |
| Thymogen | Glu-Trp | Dipeptide | ~333 Da | Immune-associated |
| Pinealon | Glu-Asp-Arg | Tripeptide | ~418 Da | Neural-associated |
| Livagen | Lys-Glu-Asp-Ala | Tetrapeptide | ~461 Da | Chromatin-associated |
As the table shows, these are among the smallest peptides studied for regulatory activity, with molecular weights well under 500 daltons. Their brevity is precisely what makes them interesting to researchers: a dipeptide such as Vilon contains only two amino acids, yet it has been examined for effects on cellular and molecular endpoints. Investigators comparing these sequences routinely check them against published certificates of analysis to confirm identity and purity before any experimental work begins.
How Peptide Bioregulators Are Studied
Because peptide bioregulators are a research class, the relevant question for any laboratory is how they are handled and evaluated experimentally, not how they might be used outside the lab.
Model Systems and Endpoints
Published work has relied on several model systems: cultured human cells such as fibroblasts and lymphocytes, aged rodent models, and shorter-lived invertebrate models used in aging research. Typical endpoints include gene-expression profiling, assessment of telomerase activity in cultured somatic cells, chromatin-structure analysis, and markers of oxidative and cellular stress. Results across these systems inform the gene-regulation hypotheses described above, but they do not translate directly to any human outcome and should not be read as evidence of one.
Sourcing, Purity, and Handling
For laboratories that acquire these compounds, material quality is a practical priority. Synthetic short peptides are typically catalogued alongside other research peptides and supplied as a lyophilized powder that is reconstituted with bacteriostatic water before in-vitro work. Confirming what a vial actually contains means reading a certificate of analysis for identity and purity, and following sound practices for choosing a research peptide supplier. Reputable suppliers publish batch-level documentation, and comparing a product against its stated specifications is a routine part of responsible research procurement. These compounds are intended strictly for controlled laboratory study, research use only, not for human consumption.
Frequently Asked Questions
What are peptide bioregulators?
Peptide bioregulators are a research class of very short peptides, generally two to four amino acids in length, studied for their proposed influence on gene expression. They are often called Khavinson peptides after the researchers who pioneered their investigation. In the laboratory they are examined as candidate regulators of transcription and chromatin state rather than as conventional receptor-binding hormones.
What are Khavinson peptides?
Khavinson peptides is an informal name for the short peptide bioregulators studied by Professor Vladimir Khavinson and collaborators at the St. Petersburg Institute of Bioregulation and Gerontology. The term covers both the original tissue-derived complexes (cytomedins) and the synthetic short peptides (cytogens) developed from them, such as Epitalon and Vilon.
How are short peptides thought to regulate genes?
The leading hypothesis is that short peptides can enter the nucleus and interact with specific DNA sequences in gene promoter regions, or with chromatin proteins, in a way that influences transcription. Some studies also report associated changes in DNA methylation. These mechanisms are the subject of ongoing preclinical research and molecular modeling, and they should be regarded as investigational rather than established.
What is Epitalon and why is it studied?
Epitalon (Ala-Glu-Asp-Gly), also spelled Epithalon, is a synthetic tetrapeptide associated with the pineal gland in this research tradition. It is one of the most frequently referenced peptide bioregulators and has been examined in cell-culture and animal studies looking at gene expression and telomerase activity. Any reported findings are limited to those preclinical contexts.
Are peptide bioregulators the same as peptide hormones?
No. Peptide hormones are typically longer chains that act on defined cell-surface receptors. Peptide bioregulators are much shorter and are studied under the different hypothesis that they act at the level of DNA and chromatin. The two categories are investigated with different assumptions and different methods.
Are peptide bioregulators approved for human use?
No. The peptide bioregulators discussed here are research compounds supplied for laboratory study only. They are research use only, not for human consumption, and nothing in this overview should be read as a health, longevity, or therapeutic claim.
References and Further Reading
- Khavinson and colleagues on short peptide bioregulators and gerontology. PubMed: Khavinson peptide bioregulators
- Studies of Epithalon and telomerase activity in cultured cells. PubMed: Epithalon telomerase
- Short peptides and the regulation of gene expression. PubMed: short peptides gene expression
- Peptide interaction with DNA and epigenetic regulation. PubMed: peptide DNA epigenetic regulation
- Vilon (Lys-Glu) dipeptide in immune and cellular models. PubMed: Vilon peptide Lys-Glu
- Geroprotective peptides in animal aging models. PubMed: Khavinson geroprotective peptides
- Pineal peptide preparations and circadian research. PubMed: pineal peptide Epithalamin
